Interviews

Alexa Simon Meara, MD, discussed how rheumatology and oncology can work together to improve outcomes for patients undergoing immunotherapy treatment for cancer.

Tarah Ballinger, MD, discusses findings from the phase 2 EAZ171 study of taxane-induced peripheral neuropathy in Black patients with breast cancer.

Peter Borchmann, MD, discusses the main takeaways from the GHSG HD21 study presented at the 2024 ASCO Annual Meeting.

In an interview with Targeted Oncology, Paolo Ghia, MD, PhD, discussed the 5-year results from the CAPTIVATE study in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Aleksander L. Chojecki, MD, discussed findings from his research on hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib.

Doris Hansen, MD, discusses the efficacy of daratumumab, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone in newly diagnosed myeloma.

In an interview with Targeted Oncology, Daniel Nguyen, MD, PhD, further discussed the findings from this phase 2 trial and the potential of vibecotamab.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the background and findings from a study comparing patients who underwent thymectomy and nephrectomy.

Jose Lutzky, MD, discusses the innovative tumor-inflitrating lymphocyte therapy for the treatment of relapsed or refractory melanoma.

In an interview with Targeted Oncology, Joe Leach, MD, highlighted the current state and future prospects of treating patients with small cell lung cancer.

Kim N. Chi, MD, FRCPC, discusses how the findings from the phase 3 MAGNITUDE trial translate into everyday practice.

Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.

Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.

Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least 1 prior line of therapy and is refractory to lenalidomide.

Halle Moore, MD, discusses some of the main concerns that patients with breast cancer have about fertility after treatment.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.